DNA甲基化与非大动脉粥样硬化型卒中相关性研究进展

doi:10.3969/j.issn.1673－5765.2023.04.002

摘要/Abstract

摘要： 缺血性卒中由多种环境因素和遗传风险因素共同决定。DNA甲基化作为一种重要的表观遗传学调控机制，可能是缺血性卒中的可遗传危险因素，对缺血性卒中的发生、发展过程产生潜在影响。缺血性卒中不同病因亚型存在特征性候选基因DNA甲基化水平改变，这对探究不同病因亚型的病理生理学过程具有重要价值。DNA甲基化是动态、可逆的表观遗传学改变，其模式可随疾病发生、发展的不同时期发生显著变化，提示DNA甲基化可作为缺血性卒中及其亚型的潜在生物标志物和治疗靶点。本文就DNA甲基化与非大动脉粥样硬化型（心源性栓塞型、小动脉闭塞型、其他明确病因型）卒中的关系进行综述，以期为缺血性卒中的诊断和治疗提供新思路。

文章导读： 本文全面介绍了与心源性栓塞型、小动脉闭塞型、其他明确病因型卒中相关的DNA甲基化改变，分析其可能的机制及可能有助于临床诊断和治疗的靶点和思路。

关键词: 脱氧核糖核酸; 甲基化; 表观遗传; 心源性栓塞型卒中; 小动脉闭塞型卒中; 其他明确病因型卒中

Abstract: Ischemic stroke is determined by a variety of environmental and genetic risk factors. As a critical epigenetic regulatory mechanism, DNA methylation may be a heritable risk factor and potentially influence the occurrence and development of ischemic stroke. There are changes in DNA methylation levels of characteristic candidate genes in different etiological subtypes of ischemic stroke, which is important value in exploring the pathophysiological processes of different stroke subtypes. DNA methylation is a dynamic and reversible epigenetic change, and its pattern can change significantly with different stages of disease, suggesting that DNA methylation can be a potential biomarker and therapeutic target for ischemic stroke and its subtypes. This article reviewed the correlation between DNA methylation and non-large artery atherosclerotic stroke (cardioembolism, small-artery occlusion and other determined etiology), to provide new ideas for the diagnosis and treatment of ischemic stroke.

Key words: DNA; Methylation; Epigenetics; Cardioembolism stroke; Small-artery occlusion stroke; Stroke of other determined etiology

姜晓晴, 瓮佳旭, 周宏宇, 李子孝, 王拥军. DNA甲基化与非大动脉粥样硬化型卒中相关性研究进展[J]. 中国卒中杂志, 2023, 18(04): 376-387.

JIANG Xiaoqing, WENG Jiaxu, ZHOU Hongyu, LI Zixiao, WANG Yongjun. Advances in Correlation between DNA Methylation and Non-Large Artery Atherosclerotic Stroke[J]. Chinese Journal of Stroke, 2023, 18(04): 376-387.

参考文献

[1] MONTANER J，RAMIRO L，SIMATS A，et al. Multilevel omics for the discovery of biomarkers and therapeutic targets for stroke[J]. Nat Rev Neurol，2020，16（5）：247-264.
[2] ADAMS H P Jr，BENDIXEN B H，KAPPELLE L J，et al. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST trial of org 10172 in acute stroke treatment[J]. Stroke，1993，24（1）：35-41.
[3] BEVAN S，TRAYLOR M，ADIB-SAMII P，et al. Genetic heritability of ischemic stroke and the contribution of previously reported candidate gene and genomewide associations[J]. Stroke，2012，43（12）：3161-3167.
[4] DOMINGUES-MONTANARI S，MENDIOROZ M，DEL RIO-ESPINOLA A，et al. Genetics of stroke：a review of recent advances[J]. Expert Rev Mol Diagn，2008，8（4）：495-513.
[5] STANZIONE R，COTUGNO M，BIANCHI F，et al. Pathogenesis of ischemic stroke：role of epigenetic mechanisms[J]. Genes（Basel），2020，11（1）：89.
[6] TAKAI D，JONES P A. Comprehensive analysis of CpG islands in human chromosomes 21 and 22[J]. Proc Natl Acad Sci U S A，2002，99（6）：3740-3745.
[7] BACCARELLI A，WRIGHT R，BOLLATI V，et al. Ischemic heart disease and stroke in relation to blood DNA methylation[J]. Epidemiology，2010，21（6）：819-828.
[8] SORIANO-TARRAGA C，LAZCANO U，GIRALT-STEINHAUER E，et al. Identification of 20 novel loci associated with ischaemic stroke. Epigenome-wide association study[J]. Epigenetics，2020，15（9）：988-997.
[9] DUBAL D B，RAU S W，SHUGHRUE P J，et al. Differential modulation of estrogen receptors（ERs）in ischemic brain injury：a role for ERalpha in estradiol-mediated protection against delayed cell death[J]. Endocrinology，2006，147（6）：3076-3084.
[10] LIN H F，HSI E，LIAO Y C，et al. Demethylation of circulating estrogen receptor alpha gene in cerebral ischemic stroke[J/OL]. PLoS One，2015，10（9）：e0139608[2022-10-11]. https://doi.org/10.1371/journal.pone.0139608.
[11] LU Y J，SAREDDY G R，WANG J，et al. Neuron-derived estrogen is critical for astrocyte activation and neuroprotection of the ischemic brain[J]. J Neurosci，2020，40（38）：7355-7374.
[12] ZHOU R P，TIAN D L，TAO Y，et al. β-Estradiol protects against acidosis-mediated and ischemic neuronal injury by promoting ASIC1a（acid-sensing ion channel 1a）protein degradation[J]. Stroke，2019，50（10）：2902-2911.
[13] HABIB P，HARMS J，ZENDEDEL A，et al. Gonadal hormones E2 and P mitigate cerebral ischemia-induced upregulation of the AIM2 and NLRC4 inflammasomes in rats[J]. Int J Mol Sci，2020，21（13）：4795.
[14] WESTBERRY J M，PREWITT A K，WILSON M E. Epigenetic regulation of the estrogen receptor alpha promoter in the cerebral cortex following ischemia in male and female rats[J]. Neuroscience，2008，152（4）：982-989.
[15] CULLELL N，SORIANO-TARRAGA C，GALLEGO-FABREGA C，et al. DNA methylation and ischemic stroke risk：an epigenome-wide association study[J]. Thromb Haemost，2022，122（10）：1767-1778.
[16] JUNG C G，KIM H J，KAWAGUCHI M，et al. Homeotic factor ATBF1 induces the cell cycle arrest associated with neuronal differentiation[J]. Development，2005，132（23）：5137-5145.
[17] MALIK R，CHAUHAN G，TRAYLOR M，et al. Multiancestry genome-wide association study of
520，000 subjects identifies 32 loci associated with stroke and stroke subtypes[J]. Nat Genet，2018，50（4）：524-537.
[18] NINDS Stroke Genetics Network，International Stroke Genetics Consortium. Loci associated with ischaemic stroke and its subtypes（SiGN）：a genome-wide association study[J]. Lancet Neurol，2016，15（2）：174-184.
[19] FATAR M，STROICK M，STEFFENS M，et al. Single-nucleotide polymorphisms of MMP-2 gene in stroke subtypes[J]. Cerebrovasc Dis，2008，26（2）：113-119.
[20] LIN H F，HSI E，HUANG L C，et al. Methylation in the matrix metalloproteinase-2 gene is associated with cerebral ischemic stroke[J]. J Investig Med，2017，65（4）：794-799.
[21] LUCIVERO V，PRONTERA M，MEZZAPESA D M，et al. Different roles of matrix metalloproteinases-2 and -9 after human ischaemic stroke[J]. Neurol Sci，2007，28（4）：165-170.
[22] ARBA F，LEIGH R，INZITARI D，et al. Blood-brain barrier leakage increases with small vessel disease in acute ischemic stroke[J]. Neurology，2017，89（21）：2143-2150.
[23] LEE E J，KIM M S，YIM N H，et al. Association of CYP26C1 promoter hypomethylation with small vessel occlusion in Korean subjects[J]. Genes（Basel），2021，12（10）：1622.
[24] ISOHERRANEN N，ZHONG G. Biochemical and physiological importance of the CYP26 retinoic acid hydroxylases[J/OL]. Pharmacol Ther，2019，204：107400[2022-10-11]. https://doi.org/10.1016/j.pharmthera.2019.107400.
[25] CAI W，WANG J L，HU M Y，et al. All trans-retinoic acid protects against acute ischemic stroke by modulating neutrophil functions through STAT1 signaling[J]. J Neuroinflammation，2019，16（1）：175.
[26] YU S J，AIRAVAARA M，WU K J，et al. 9-CIS retinoic acid induces neurorepair in stroke brain[J]. Sci Rep，2017，7（1）：4512.
[27] GUO X F，LI Z，ZHOU Y，et al. Metabolic profile for prediction of ischemic stroke in Chinese hypertensive population[J]. J Stroke Cerebrovasc Dis，2019，28（4）：1062-1069.
[28] YU Y R，ZHANG H，SONG Y，et al. Plasma retinol and the risk of first stroke in hypertensive adults：a nested case-control study[J]. Am J Clin Nutr，2019，109（2）：449-456.
[29] ROWLING M J，Schalinske K L. Retinoic acid and glucocorticoid treatment induce hepatic glycine N-methyltransferase and lower plasma homocysteine concentrations in rats and rat hepatoma cells[J]. J Nutr，2003，133（11）：3392-3398.
[30] LARSSON S C，TRAYLOR M，MARKUS H S. Homocysteine and small vessel stroke：a mendelian randomization analysis[J]. Ann Neurol，2019，85（4）：495-501.
[31] AMARENCO P，BOGOUSSLAVSKY J，CAPLAN L R，et al. Classification of stroke subtypes[J]. Cerebrovasc Dis，2009，27（5）：493-501.
[32] KITCHING A R，ANDERS H J，BASU N，et al. ANCA-associated vasculitis[J]. Nat Rev Dis Primers，2020，6（1）：71.
[33] YANG J J，PENDERGRAFT W F，ALCORTA D A，et al. Circumvention of normal constraints on granule protein gene expression in peripheral blood neutrophils and monocytes of patients with antineutrophil cytoplasmic autoantibody-associated glomerulonephritis[J]. J Am Soc Nephrol，2004，15（8）：2103-2114.
[34] JONES B E，YANG J J，MUTHIGI A，et al. Gene-specific DNA methylation changes predict remission in patients with ANCA-associated vasculitis[J]. J Am Soc Nephrol，2017，28（4）：1175-1187.
[35] CIAVATTA D J，YANG J，PRESTON G A，et al. Epigenetic basis for aberrant upregulation of autoantigen genes in humans with ANCA vasculitis[J]. J Clin Invest，2010，120（9）：3209-3219.
[36] GUO Y L，ZHAO S，WANG G G. Polycomb gene silencing mechanisms：PRC2 chromatin targeting，H3K27me3 'Readout'，and phase separation-based compaction[J]. Trends Genet，2021，37（6）：547-565.
[37] TERRADES-GARCIA N，CID M C. Pathogenesis of giant-cell arteritis：how targeted therapies are influencing our understanding of the mechanisms involved[J/OL]. Rheumatology（Oxford），2018，57（suppl_2）：ii51-ii62[2022-10-11]. https://doi.org/10.1093/rheumatology/kex423.
[38] COIT P，DE LOTT L B，NAN B，et al. DNA methylation analysis of the temporal artery microenvironment in giant cell arteritis[J]. Ann Rheum Dis，2016，75（6）：1196-1202.
[39] VAN SLEEN Y，WANG Q，VAN DER GEEST K S M，et al. Involvement of monocyte subsets in the immunopathology of giant cell arteritis[J]. Sci Rep，2017，7（1）：6553.
[40] ESTUPIÑÁN-MORENO E，ORTIZ-FERNÁNDEZ L，LI T，et al. Methylome and transcriptome profiling of giant cell arteritis monocytes reveals novel pathways involved in disease pathogenesis and molecular response to glucocorticoids[J]. Ann Rheum Dis，2022，81（9）：1290-1300.
[41] OZEN S，SAG E. Childhood vasculitis[J/OL]. Rheumatology（Oxford），2020，59（Suppl 3）：iii95-iii100[2022-10-11]. https://doi.org/10.1093/rheumatology/kez599.
[42] DUAN J Y，LOU J，ZHANG Q，et al. A genetic variant rs1801274 in FCGR2A as a potential risk marker for Kawasaki disease：a case-control study and meta-analysis[J/OL]. PLoS One，2014，9（8）：e103329[2022-10-11]. https://doi.org/10.1371/journal. pone.0103329.
[43] KUO H C，CHANG J C，KUO H C，et al. Identification of an association between genomic hypomethylation of FCGR2A and susceptibility to Kawasaki disease and intravenous immunoglobulin resistance by DNA methylation array[J]. Arthritis Rheumatol，2015，67（3）：828-836.
[44] LI S C，CHAN W C，HUANG Y H，et al. Major methylation alterations on the CpG markers of inflammatory immune associated genes after IVIG treatment in Kawasaki disease[J/OL]. BMC Med Genomics，2016，9 Suppl 1：37[2022-10-11]. https://doi.org/10.1186/s12920-016-0197-2.
[45] ANANIA J C，CHENOWETH A M，WINES B D，et al. The human FcγRII（CD32）family of leukocyte FcR in health and disease[J/OL]. Front Immunol，2019，10：464[2022-10-11]. https://doi.org/10.3389/fimmu.2019.00464.
[46] HUANG Y H，LI S C，HUANG L H，et al. Identifying genetic hypomethylation and upregulation of Toll-like receptors in Kawasaki disease[J/OL]. Oncotarget，2017，8（7）：11249-11258[2022-10-11]. https://doi.org/10.18632/oncotarget.14497.
[47] VOGELPOEL L T，HANSEN I S，VISSER M W，et al. FcγRIIa cross-talk with TLRs，IL-1R，and IFNγR selectively modulates cytokine production in human myeloid cells[J]. Immunobiology，2015，220（2）：193-199.
[48] GRECO A，DE VIRGILIO A，RALLI M，et al. Behcet's disease：new insights into pathophysiology，clinical features and treatment options[J]. Autoimmun Rev，2018，17（6）：567-575.
[49] HUGHES T，TURE-OZDEMIR F，ALIBAZ-ONER F，et al. Epigenome-wide scan identifies a treatment-responsive pattern of altered DNA methylation among cytoskeletal remodeling genes in monocytes and CD4+ T cells from patients with Behcet's disease[J]. Arthritis Rheumatol，2014，66（6）：1648-1658.
[50] LIU Y C，WU X Z，NIE S，et al. Methylation of phospholipase A2 group Ⅶ gene is associated with brain arteriovenous malformations in Han Chinese populations[J]. J Mol Neurosci，2020，70（7）：1056-1063.
[51] CHEN X S，LIU Y C，ZHOU S J，et al. Methylation of the CDKN2A gene increases the risk of brain arteriovenous malformations[J]. J Mol Neurosci，2019，69（2）：316-323.
[52] WANG Z P，ZHAO J K，SUN J，et al. Sex-dichotomous effects of NOS1AP promoter DNA methylation on intracranial aneurysm and brain arteriovenous malformation[J/OL]. Neurosci Lett，2016，621：47-53[2022-10-11]. https://doi.org/10.1016/j.neulet.2016.04.016.
[53] ZHOU S J，GAO X，SUN J，et al. DNA methylation of the PDGFD gene promoter increases the risk for intracranial aneurysms and brain arteriovenous malformations[J]. DNA Cell Biol，2017，36（6）：436-442.
[54] SUNG H Y，LEE J Y，PARK A K，et al. Aberrant promoter hypomethylation of sortilin 1：a moyamoya disease biomarker[J]. J Stroke，2018，20（3）：350-361.
[55] CONLON D M. Role of sortilin in lipid metabolism[J]. Curr Opin Lipidol，2019，30（3）：198-204.
[56] ARBER D A，ORAZI A，HASSERJIAN R，et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia[J]. Blood，2016，127（20）：2391-2405.
[57] SZYBINSKI J，MEYER S C. Genetics of myeloproliferative neoplasms[J]. Hematol Oncol Clin North Am，2021，35（2）：217-236.
[58] PASSAMONTI F，ELENA C，SCHNITTGER S，et al. Molecular and clinical features of the myeloproliferative neoplasm associated with JAK2 exon 12 mutations[J]. Blood，2011，117（10）：2813-2816.
[59] ORTMANN C A，KENT D G，NANGALIA J，et al. Effect of mutation order on myeloproliferative neoplasms[J]. N Engl J Med，2015，372（7）：601-612.
[60] NANGALIA J，NICE F L，WEDGE D C，et al. DNMT3A mutations occur early or late in patients with myeloproliferative neoplasms and mutation order influences phenotype[J/OL]. Haematologica，2015，100（11）：e438-e442[2022-10-11]. https://doi.org/10.3324/haematol.2015.129510.
[61] ISSA G C，DINARDO C D. Acute myeloid leukemia with IDH1 and IDH2 mutations：2021 treatment algorithm[J]. Blood Cancer J，2021，11（6）：107.
[62] DELHOMMEAU F，DUPONT S，DELLA VALLE V，et al. Mutation in TET2 in myeloid cancers[J]. N Engl J Med，2009，360（22）：2289-2301.
[63] PÉREZ C，PASCUAL M，MARTÍN-SUBERO J I，et al. Aberrant DNA methylation profile of chronic and transformed classic Philadelphia-negative myeloproliferative neoplasms[J]. Haematologica，2013，98（9）：1414-1420.
[64] TANIGUCHI K，KARIN M. NF-κB，inflammation，immunity and cancer：coming of age[J]. Nat Rev Immunol，2018，18（5）：309-324.
[65] PETRI M. Antiphospholipid syndrome[J/OL]. Transl Res，2020，225：70-81[2022-10-11]. https://doi.org/10.1016/j.trsl.2020.04.006.
[66] WEEDING E，COIT P，YALAVARTHI S，et al. Genome-wide DNA methylation analysis in primary antiphospholipid syndrome neutrophils[J/OL]. Clin Immunol，2018，196：110-116[2022-10-11]. https://doi.org/10.1016/j.clim.2018.11.011.
[67] YANG W L，SHEN N，YE D Q，et al. Genome-wide association study in Asian populations identifies variants in ETS1 and WDFY4 associated with systemic lupus erythematosus[J/OL]. PLoS Genet，2010，6（2）：e1000841[2022-10-11]. https://doi.org/10.1371/journal. pgen.1000841.
[68] GLAS J，WAGNER J，SEIDERER J，et al. PTPN2 gene variants are associated with susceptibility to both Crohn's disease and ulcerative colitis supporting a common genetic disease background[J/OL]. PLoS One，2012，7（3）：e33682[2022-10-11]. https://doi.org/10.1371/journal. pone.0033682.
[69] OKADA Y，TERAO C，IKARI K，et al. Meta-analysis identifies nine new loci associated with rheumatoid arthritis in the Japanese population[J]. Nat Genet，2012，44（5）：511-516.
[70] PATSOURAS M D，KARAGIANNI P，KOGIONOU P，et al. Differential CpG methylation of the promoter of interleukin 8 and the first intron of tissue factor in Antiphospholipid syndrome[J/OL]. J Autoimmun，2019，102：159-166[2022-10-11]. https://doi.org/10.1016/j.jaut.2019.05.001.
[71] KIRIAKIDOU M，CHING C L. Systemic lupus erythematosus[J/OL]. Ann Intern Med，2020，172（11）：Itc81-itc96[2022-10-11]. https://doi.org/10.7326/AITC202006020.
[72] RICHARDSON B. Effect of an inhibitor of DNA methylation on T cells. II. 5-Azacytidine induces self-reactivity in antigen-specific T4+ cells[J]. Hum Immunol，1986，17（4）：456-470.
[73] CORVETTA A，DELLA BITTA R，LUCHETTI M M，et al. 5-Methylcytosine content of DNA in blood，synovial mononuclear cells and synovial tissue from patients affected by autoimmune rheumatic diseases[J]. J Chromatogr，1991，566（2）：481-491.
[74] LU Q J，WU A，RICHARDSON B C. Demethylation of the same promoter sequence increases CD70 expression in lupus T cells and T cells treated with lupus-inducing drugs[J]. J Immunol，2005，174（10）：6212-6219.
[75] LU Q J，WU A，TESMER L，et al. Demethylation of CD40LG on the inactive X in T cells from women with lupus[J]. J Immunol，2007，179（9）：6352-6358.
[76] LIN S Y，HSIEH S C，LIN Y C，et al. A whole genome methylation analysis of systemic lupus erythematosus：hypomethylation of the IL10 and IL1R2 promoters is associated with disease activity[J]. Genes Immun，2012，13（3）：214-220.
[77] MI X B，ZENG F Q. Hypomethylation of interleukin-4 and -6 promoters in T cells from systemic lupus erythematosus patients[J]. Acta Pharmacol Sin，2008，29（1）：105-112.
[78] TANG C，LI Y，LIN X J，et al. Hypomethylation of interleukin 6 correlates with renal involvement in systemic lupus erythematosus[J]. Cent Eur J Immunol，2014，39（2）：203-208.
[79] ZHAO M，ZHOU Y，ZHU B C，et al. IFI44L promoter methylation as a blood biomarker for systemic lupus erythematosus[J]. Ann Rheum Dis，2016，75（11）：1998-2006.
[80] OKADA M，OGASAWARA H，KANEKO H，et al. Role of DNA methylation in transcription of human endogenous retrovirus in the pathogenesis of systemic lupus erythematosus[J]. J Rheumatol，2002，29（8）：1678-1682.
[81] PIOTROWSKI P C，DURIAGIN S，JAGODZINSKI P P. Expression of human endogenous retrovirus clone 4-1 may correlate with blood plasma concentration of anti-U1 RNP and anti-Sm nuclear antibodies[J]. Clin Rheumatol，2005，24（6）：620-624.
[82] WARE R E，DE MONTALEMBERT M，TSHILOLO L，et al. Sickle cell disease[J/OL]. Lancet，2017，390（10091）：311-323[2022-10-11]. https://doi.org/10.1016/S0140-6736（17）30193-9.
[83] PIEL F B，STEINBERG M H，REES D C. Sickle cell disease[J]. N Engl J Med，2017，376（16）：1561-1573.
[84] EATON W A，BUNN H F. Treating sickle cell disease by targeting HbS polymerization[J]. Blood，2017，129（20）：2719-2726.
[85] XU J，BAUER D E，KERENYI M A，et al. Corepressor-dependent silencing of fetal hemoglobin expression by BCL11A[J]. Proc Natl Acad Sci U S A，2013，110（16）：6518-6523.
[86] SEELAN R S，MUKHOPADHYAY P，PISANO M M，et al. Effects of 5-Aza-2'-deoxycytidine（decitabine）on gene expression[J]. Drug Metab Rev，2018，50（2）：193-207.
[87] MOLOKIE R，LAVELLE D，GOWHARI M，et al. Oral tetrahydrouridine and decitabine for non-cytotoxic epigenetic gene regulation in sickle cell disease：a randomized phase 1 study[J/OL]. PLoS Med，2017，14（9）：e1002382[2022-10-11]. https://doi.org/10.1371/journal. pmed.1002382.